M. Scott Lucia, MD, University of Colorado, Denver, Aurora, Colorado, discusses if there are genomic tests to help determine the need for a repeat biopsy.

Interview produced by Prostatepedia

Keywords: genomic tests, repeat biopsy, prostate cancer

ABOUT THE AUTHOR

M. Scott Lucia, MD, is Professor and Vice Chair of the Department of Pathology and Director of Anatomic Pathology and of the Prostate Diagnostic Laboratory at the University of Colorado Anschutz Medical Campus (UCAMC) School of Medicine. He also serves as the Director of the Prostate Cancer Research Laboratories at UCAMC and of the UCAMC Biorepository Core Facility. Dr. Lucia received his MD from the University of Colorado School of Medicine in 1988. He completed his internship and residency in pathology at the University of Colorado in 1993. He was a research fellow in the Laboratory of Chemoprevention at the National Institutes of Health from 1993 to 1995, before returning to the University of Colorado in 1995.

Dr. Lucia served as the primary pathologist for the Prostate Cancer Prevention Trial (PCPT) and Vitamin E and Selenium Chemoprevention Trial (SELECT), sponsored by the Southwest Oncology Group; the Medical Therapy of Prostate Symptoms (MTOPS) trial, sponsored by the NIDDK; and the Reduction with Dutasteride of Clinical Progression Events in Expectant Management of Prostate Cancer (REDEEM), sponsored by GlaxoSmithKline. He directs the operation of several tissue and serum biorepositories for prostate and prostatic diseases, including those for the PCPT, MTOPS, SELECT, and the University of Colorado Cancer Center Prostate Biorepository. He has authored or co-authored over 180 peer-reviewed articles, reviews, editorials, and book chapters. His primary areas of interest include pathology of prostate cancer and hyperplasia, early detection and prevention of prostate cancer, prostate cancer biomarkers, and mechanisms of carcinogenesis.